Skip to main content

Table 3 Patient Outcomes

From: Propensity score adjusted comparison of three-factor versus four-factor prothrombin complex concentrate for emergent warfarin reversal: a retrospective cohort study

Outcome PCC3 (n = 57) PCC4 (n = 23) p
Patients achieving INR ≤ 1.5, n (%) 18 (31.6%) 20 (87.0%) < 0.001
 Intracranial bleeding 10 (32.3%) 16 (84.2%)  
 Gastrointestinal bleeding 4 (40.0%) 2 (100%)  
 Other bleeding 4 (75%) 2 (100%)  
Death during hospitalization, n (%) 14 (24.7%) 8 (34.8%) 0.52
 Intracranial bleeding 10 (32.3%) 7 (36.8%)  
 Gastrointestinal bleeding 1 (10.0%) 0 (0%)  
 Other bleeding 3 (75%) 1 (50%)  
Length of stay
 Overall 6.0 (4.0–11.0) 6.0 (2.5–10.0) 0.47
 Survivors 6.5 (4.0–10.0) 6.0 (3.0–9.5) 0.52
Thromboembolic events, n (%) 5 (8.8%) 2 (8.7%) 1.0
  1. INR international normalized ratio, PCC prothrombin complex concentrate, PCC3 3-factor PCC, PCC4 4-factor PCC